This study is for adults aged 18-65 who are receiving a living donor kidney transplant. It explores whether a special preparation, including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG), and infusions of donor hematopoietic stem cells and recipient regulatory T cells (Tregs), can help you eventually stop taking anti-rejection medications. The goal is to see if your body can learn to accept the new kidney without these drugs. Success would mean that participants develop a stable mix of donor and recipient immune cells (chimerism) and can stop anti-rejection drugs like Mycophenolate mofetil (MMF) and tacrolimus by 18 months after transplant, without the kidney being rejected. The study plans to enroll 22 participants, but its current status is unclear.

Study design

This is an interventional study planning to enroll 22 participants. It tests a specific treatment approach for living donor kidney transplant recipients.

What's involved

Participants will receive a preparatory regimen before their kidney transplant, followed by infusions of donor stem cells and recipient Tregs. Immunosuppressive drugs will be gradually reduced if certain conditions are met.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for at least 18 months to check for sustained mixed chimerism and successful withdrawal from immunosuppressive drugs.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.